Co-existence of EGFR, KRAS, BRAF, PIK3CA mutations and ALK re-arrangement in a comprehensive cohort of 326 consecutive Spanish non-squamous NSCLC patients

Molecular information from 326 non-squamous NSCLC patients is presented with the aim to determine driver mutation co-existence and response to treatment. To our knowledge, limited data has been presented on this subject. We find 12 % rate of mutational co-existence using NGS and ALK inmunohistochemical analysis. Most cases of co-existing mutations do not respond well to targeted treatment.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oNySFQ
via IFTTT